---
title: "PAVmed | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286562396.md"
datetime: "2026-05-15T12:08:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286562396.md)
  - [en](https://longbridge.com/en/news/286562396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286562396.md)
---

# PAVmed | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22 K

Revenue: As of FY2026 Q1, the actual value is USD 22 K, missing the estimate of USD 74 K.

EPS: As of FY2026 Q1, the actual value is USD -4.42.

#### Operating Expenses

-   Operating expenses for PAVmed Inc. were approximately $8.1 million for the three months ended March 31, 2026, which included $0.2 million in stock-based compensation expenses.
-   Total operating expenses for PAVmed Inc. were $8,057 thousand for the three months ended March 31, 2026, compared to $5,454 thousand for the three months ended March 31, 2025.

#### GAAP Net Loss Attributable to Common Stockholders

-   GAAP net loss attributable to common stockholders for PAVmed Inc. was approximately -$7.0 million for the three months ended March 31, 2026.
-   Net income (loss) attributable to common stockholders for PAVmed Inc. was -$6,988 thousand for the three months ended March 31, 2026, compared to $17,695 thousand for the three months ended March 31, 2025.

#### Non-GAAP Adjusted Loss

-   The non-GAAP adjusted loss for PAVmed Inc. was approximately -$1.9 million for the three months ended March 31, 2026.
-   Non-GAAP adjusted (loss) for PAVmed Inc. was -$1,851 thousand for the three months ended March 31, 2026, compared to -$910 thousand for the three months ended March 31, 2025.

#### Cash and Cash Equivalents

-   PAVmed Inc. had cash and cash equivalents of $6.5 million as of March 31, 2026, compared to $1.5 million as of December 31, 2025.

#### EsoGuard® Esophageal DNA Test Revenue

-   Lucid Diagnostics Inc. recognized $1.3 million in EsoGuard® Esophageal DNA Test revenue for the first quarter of 2026.

#### EsoGuard Tests Processed

-   Lucid Diagnostics Inc. processed 3,177 EsoGuard tests in the first quarter of 2026.

#### Cash Position (Lucid Diagnostics Inc.)

-   Lucid Diagnostics Inc. strengthened its balance sheet with an underwritten public offering of common stock, netting approximately $17 million in proceeds.
-   The company ended the first quarter of 2026 with $45 million in proforma cash, extending its runway into 2027.

#### Outlook / Guidance

-   PAVmed Inc. is positioned to focus on execution across its core businesses and evaluate additional asset acquisition opportunities aligned with its long-term growth strategy, following a simplified capital structure and strengthened balance sheet.
-   Veris Health Inc. expects to begin presubmission and testing activities soon for its implantable physiological monitor, in support of a planned FDA 510(k) submission, and continues to expand its commercial engagement with The Ohio State University’s James Cancer Hospital.
-   Lucid Diagnostics Inc. continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage.

### Related Stocks

- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)

## Related News & Research

- [PAVmed Reports Q1 2026 Results and Business Update](https://longbridge.com/en/news/286567652.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)